|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Boehringer Ingelheim Pharmaceuticals |
| Information provided by: | Boehringer Ingelheim Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT00062660 |
Purpose
To provide early access to tipranavir and evaluate the safety and tolerance of tipranavir combined with low dose of ritonavir in patients with progressive, HIV-1 disease who have failed or are intolerant to currently approved treatments for HIV infection, who are unable to participate in another tipranavir controlled clinical trial and have an urgent need for anti-HIV treatment.
| Condition | Intervention |
|
HIV Infections |
Drug: Tipranavir Capsules Drug: Tipranavir Oral Solution |
| MedlinePlus related topics: | AIDS |
| ChemIDplus related topics: | Tipranavir |
| Study Type: | Expanded Access |
| Official Title: | Emergency Use Program for Highly Treatment-Experienced HIV+ Patients |
Eligibility
| Ages Eligible for Study: | 2 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Patients aho have a positive serology HIV antibody test confirmed by Western blot, p24 antigen assay, HIV-1 RNA or HIV culture and are highly pre-treated and virus resistant to multiple protease inhibitors.
Exclusion Criteria:
Contacts and Locations| Contact: Boehringer Ingelheim Study Coordinator | clintriage@boehringer-ingelheim.com |
![]() |
Show 127 Study Locations |
| Boehringer Ingelheim Pharmaceuticals |
| Study Chair: | Boehringer Ingelheim | Boehringer Ingelheim Pharmaceuticals |
More Information
| Responsible Party: | Boehringer Ingelheim ( Boehringer Ingelheim, Study Chair ) |
| Study ID Numbers: | 1182.58 |
| First Received: | June 10, 2003 |
| Last Updated: | July 1, 2008 |
| ClinicalTrials.gov Identifier: | NCT00062660 |
| Health Authority: | United States: Food and Drug Administration; Sweden:; Spain:; Portugal:; Netherlands:; Italy:; Greece:; Germany:; France:; Denmark:; Canada:; Belgium:; Australia:; Great Britain:; Switzerland:; Austria:; Austria: |
|
|
|
|